Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $75.5 million versus the consensus estimate of $66.6 million.

GUIDANCE:

Puma Biotech sees Q1 2026 revenue of $38-42 million, versus the consensus of $49 million.

Puma Biotech sees FY2026 revenue of $214-221 million, versus the consensus of $220 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.